6 results ยท Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell CancerClear-cell metastatic renal cell carcinoma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, carcinoma, clear cell renal carcinoma, epithelial neoplasm, kidney cancer, kidney disorder, neoplasm, renal cell carcinoma, urinary system disorderRecruitingPhase 1 / Phase 22026-10-08NCT07227415
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.Carcinoma, Ductal, Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Ductal, Lobular, and Medullary, Thoracic Neoplasms, adenocarcinoma, bronchial neoplasm, bronchogenic carcinoma, carcinoma, colonic disorder, colonic neoplasm, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, epithelial neoplasm, intestinal disorder, lung disorder, lung neoplasm, malignant endocrine neoplasm, neoplasm, non-small cell lung carcinoma, pancreas disorder, pancreatic ductal adenocarcinoma, pancreatic neoplasm, rectal disorder, rectal neoplasm, respiratory system disorder, respiratory tract neoplasmActive, not recruitingPhase 12026-09-24NCT06447662
AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)Genital Diseases, Male Urogenital Diseases, Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorderActive, not recruitingPhase 1 / Phase 22026-09-03NCT07285694
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, endocrine system disorder, epithelial neoplasm, glioma, lung disorder, lung neoplasm, malignant endocrine neoplasm, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, neuroepithelial neoplasm, non-small cell lung carcinoma, primitive neuroectodermal tumor, respiratory system disorder, respiratory tract neoplasm, skin disorder, skin neoplasm, thyroid gland disorder, thyroid tumorActive, not recruitingPhase 12026-09-01NCT05355701
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast CancerHER2-positive Breast CancerActive, not recruitingPhase 32026-07-23NCT03975647
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal CancersBiliary Tract Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, biliary tract disorder, carcinoma, cholangiocarcinoma, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, epithelial neoplasm, esophageal adenocarcinoma, esophageal disorder, gallbladder carcinoma, gallbladder disorder, gallbladder neoplasm, gastric adenocarcinoma, gastric neoplasm, intestinal disorder, neoplasm, rectal disorder, stomach disorderActive, not recruitingPhase 22026-02-24NCT04430738